학술논문
P.065 Comparison in outcomes by sex in acute ischemic stroke patients treated with alteplase versus tenecteplase: a subgroup analysis of AcT
Document Type
Article
Author
Kim, DJ; Singh, N; Catanese, L; Buck, BH; Deschaintre, Y; Coutts, SB; Khosravani, H; Appireddy, R; Moreau, F; Gubitz, G; Tkach, A; Dowlatshahi, D; Medvedev, G; Mandzia, J; Pikula, A; Shankar, J; Williams, H; Manosalva, H; Siddiqui, M; Zafar, A; Imoukhuede, O; Hunter, G; Phillips, S; Hill, MD; Poppe, AY; Ademola, A; Shamy, M; Bala, F; Sajobi, TT; Swartz, RH; Almekhlafi, M; Menon, BK; Field, TS
Source
The Canadian Journal of Neurological Sciences; June 2023, Vol. 50 Issue: Supplement 2 pS76-S76, 1p
Subject
Language
ISSN
03171671
Abstract
Background: Sex differences in treatment response to intravenous thrombolysis (IVT) are poorly characterized. We compared sex-disaggregated outcomes in patients receiving IVT for acute ischemic stroke in the Alteplase compared to Tenecteplase (AcT) trial, a Canadian multicentre, randomised trial. Methods: In this post-hoc analysis, the primary outcome was excellent functional outcome (modified Rankin Score [mRS] 0-1) at 90 days. Secondary and safety outcomes included return to baseline function, successful reperfusion (eTICI≥2b), death and symptomatic intracerebral hemorrhage. Results: Of 1577 patients, there were 755 women and 822 men (median age 77 [68-86]; 70 [59-79]). There were no differences in rates of mRS 0-1 (aRR 0.95 [0.86-1.06]), return to baseline function (aRR 0.94 [0.84-1.06]), reperfusion (aRR 0.98 [0.80-1.19]) and death (aRR 0.91 [0.79-1.18]). There was no effect modification by treatment type on the association between sex and outcomes. The probability of excellent functional outcome decreased with increasing onset-to-needle time. This relation did not vary by sex (pinteraction0.42). Conclusions: The AcT trial demonstrated comparable functional, safety and angiographic outcomes by sex. This effect did not differ between alteplase and tenecteplase. The pragmatic enrolment and broad national participation in AcT provide reassurance that there do not appear to be sex differences in outcomes amongst Canadians receiving IVT.